<DOC>
	<DOCNO>NCT00666263</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( effect grip strength disability ) safety/tolerability IGIV , 10 % subject Multifocal Motor Neuropathy .</brief_summary>
	<brief_title>Study Effectiveness Intravenous Immune Globulin ( 10 % ) Treatment Multifocal Motor Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Written inform consent obtain participant prior studyrelated procedure study product administration Diagnosis definite probable MMN base criterion American Association Electrodiagnostic Medicine ( AAEM ) ( Olney et al. , 2003 , see Section 15.1 full length publication ) . Conduction block identify drop amplitude . Diagnosis base chart record ) Hand grip ( finger flexor ) weakness Medical Research Council ( MRC ) grade 4 less disease onset appear prior screening ; b ) No upper motor sign c ) No bulbar cranial sign symptom ; ) No clinically identifiable sensory abnormality Must stable regimen IGIV least 3 month prior first study product administration Treatment interval IGIV 2 5 week ( +/ 3 day ) Dose IGIV 0.4 2.0 g per kg BW infusion cycle Participants adult , male female , least 18 year age If female capable bearing child negative urine pregnancy test result enrollment agree employ adequate birth control measure duration study Ability willingness travel study site infusion assessment require protocol Any clinical electrophysiological evidence coexist neuropathy may interfere outcome assessment , diabetic neuropathy , toxic neuropathy , neuropathy due systemic lupus erythematosus Treatment immunosuppressive agent besides IGIV , demonstrate efficacy MMN cyclophosphamide 3 month prior enrollment ( treatment Rituximab 12 month prior enrollment ) . Prestudy treatment mycophenolate mofetil azathioprine permit dose stable 3 month prior enrollment . Cerebrospinal fluid protein &gt; 100 mg/dL ( do part previous evaluation ) Participants positive enrollment one following : Hepatitis B surface antigen ( HBsAg ) , polymerase chain reaction ( PCR ) Hepatitis C ( HCV ) , PCR human immunodeficiency virus ( HIV ) Type 1 Participants level alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal test laboratory Participants neutropenia ( define absolute neutrophil count [ ANC ] â‰¤1000/mm^3 ) Participants serum creatinine level great 1.5 time upper limit normal age gender Participants malignancy adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix Participants history thrombotic episode ( deep vein thrombosis , myocardial infarction , cerebrovascular accident ) Participants receive blood blood product exposure IGIV , subcutaneous immunoglobulin , immune serum globulin ( ISG ) preparation , albumin within 6 month prior enrollment Participants ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow IGIV human albumin Participants immunoglobulin A ( IgA ) deficiency know anti IgA antibody Participants use another investigational product device within 30 day prior enrollment Participants unable unwilling meet requirement study If female , pregnant lactating time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>